Myriad Genetics (MYGN) Other financing activities (2009 - 2025)

Myriad Genetics (MYGN) has reported Other financing activities for 15 consecutive years, with $600000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Other financing activities rose 250.0% year-over-year to $600000.0; the TTM figure through Dec 2025 stood at -$2.8 million (up 22.22% YoY), while the FY2025 annual figure was $3.3 million, up 925.0% from the prior year.
• Other financing activities advanced to $600000.0 in Q4 2025 per MYGN's latest filing, from -$400000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $39.9 million in Q3 2021 and bottomed at -$3.9 million in Q4 2022.
• Historically, Other financing activities has averaged $7.4 million across 5 years, with a median of $750000.0 in 2022.
• Annual changes were most pronounced in 2021 — Other financing activities soared 8733.33% — and 2022, when it plunged 316.67%.
• Myriad Genetics' Other financing activities stood at $1.8 million in 2021, then plunged by 316.67% to -$3.9 million in 2022, then surged by 94.87% to -$200000.0 in 2023, then sank by 100.0% to -$400000.0 in 2024, then jumped by 250.0% to $600000.0 in 2025.
• Business Quant data shows MYGN's Other financing activities at $600000.0 in Q4 2025, -$400000.0 in Q4 2024, and -$3.0 million in Q3 2024.